Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Trends in the use of Partial Nephrectomy for cT1 Renal Tumors: analysis of a 10-yr European Multicenter Dataset
Ist Teil von
European journal of surgical oncology, 2016-11, Vol.42 (11), p.1729-1735
Ort / Verlag
England: Elsevier Ltd
Erscheinungsjahr
2016
Quelle
Elsevier ScienceDirect Journals
Beschreibungen/Notizen
Abstract Aim Although extensively addressed in US registries, the utilitazion rate of Partial Nephrectomy has been poorly addressed in European settings. Our aim is to evaluate the impact of hospital volume on the use of PN for cT1 renal tumors. Methods 2526 patients with cT1N0M0 renal tumors treated with either PN or radical nephrectomy at 10 European centres in the last decade were included in the analysis. Joinpoint regression analysis was used to identify significant changes over time in linear slope of the trend for each center. The correlation between yearly caseload and the slopes was assessed with the non-parametric Spearman test. Coincident pairwise tests and regression analyses were used to generate and compare the trends of high-volume (HV), mid-volume (MV) and low-volume (LV) groups. Results Yearly caseload was significantly associated with increased use of PN (R=0.69, p=0.028). The utilization rate of PN was stable at LV centres (p=0.67, p=0.7, p=0.76, for cT1, cT1a, and cT1b tumors, respectively), while increased significantly at MV (p=0.002, 0.0005 and 0.007, respectively) and HV centers (all p<0.0001). Regression analysis confirmed the trends for HV and MV as significantly different from those observed in LV centres (all p≤0.002) and highlighted significant differences also between MV and HV centres (all p≤0.03). Conclusions We confirmed the association between caseload and the use of PN for cT1 tumors. Our findings suggest that a minimum caseload might turn the tide also in LV centres while a selective referral to HV centers for cT1b tumors should be considered.